Unknown PHASE3 INTERVENTIONAL 2-arm NCT01699230

Potential Effects of Omega 3 Supplementation on Cardiomyocytes Membranes for Patients With Coronary Atherosclerosis? (CORONOMEGA3)

Sponsor: University Hospital, Clermont-Ferrand

Interventions Omega 3

Updated 5 times since 2017 Last updated: Oct 1, 2012 Started: Mar 31, 2011 Primary completion: May 31, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Coronary Atherosclerosis and is currently ongoing. University Hospital, Clermont-Ferrand leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Clermont-Ferrand
Université d'Auvergne

Data source: University Hospital, Clermont-Ferrand

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Clermont-Ferrand, France